Fundacion MEDINA has entered into a contract research collaboration with Cubist Pharmaceuticals to discover novel antibiotics from Cubist's and MEDINA's proprietary and natural product libraries.
The alliance will be focused on going together with Cubist's drug discovery programs with new lead compounds in the development of new anti-bacterial drugs.
Fundacion MEDINA scientific director Olga Genilloud said the partnership represents a strategic collaboration to identify novel drugs in the area of infectious diseases from the exploitation of the unique natural products resources from Fundacion MEDINA.
"MEDINA provides the expertise and tools for maximising the probability of success in the collaboration with Cubist and the discovery of promising compounds for the treatment of serious multidrug resistant infections," Genilloud added.
MEDINA offers a platform for natural products discovery and opportunities to identify scaffold unknown in synthetic libraries to respond to unmet clinical needs.
